THE REPORT by the Institute of Medicine (IOM)1 was developed from an IOM study requested and funded by the US Food and Drug Administration (FDA). It was prompted by the controversy over the approval process for triazolam (Halcion; Upjohn Co, Kalamazoo, Mich). Although an FDA task force already considered the drug safe and effective when used according to the labeling, an independent panel was considered necessary.
Klein DF. The Report by the Institute of Medicine and Postmarketing Surveillance. Arch Gen Psychiatry. 1999;56(4):353-354. doi:10.1001/archpsyc.56.4.353